Inventor · disambiguated record
Yi Liu
Also filed as: LIU YI · LIU YI-LING
2 granted patents·7 pending applications·2 citations·filing 2007–2024
36Inventor score
Files withBOEHRINGER INGELHEIM INT5NATIONAL HEALTH RES INST2BAYER SCHERING PHARMA AG1UNIV JOHNS HOPKINS1
Top patents by PatentIndex Score
9 records- 0175US10246715B1CpG-oligodeoxynucleotide, immunogenic composition including the same, and method of inducing immune response by the sameNATIONAL HEALTH RES INST·Filed 2017·Granted Apr 2, 2019·2 cites·15 claims
- 0274US2025025466A1New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseasesBOEHRINGER INGELHEIM INT·Filed 2024·Application pending·0 cites
- 0374US2025017934A1New therapeutic combinations for the treatment of Progressive Fibrosing interstitial lung diseasesBOEHRINGER INGELHEIM INT·Filed 2024·Application pending·0 cites
- 0469US2023181590A1New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseasesBOEHRINGER INGELHEIM INT·Filed 2022·Application pending·0 cites
- 0569US2023190754A1Therapeutic combinations for the treatment of Progressive Fibrosing interstitial lung diseasesBOEHRINGER INGELHEIM INT·Filed 2022·Application pending·0 cites
- 0666US11898147B2CpG-oligodeoxynucleotide compounds in combination with immune modulators for cancer immunotherapyNATIONAL HEALTH RES INST·Filed 2021·Granted Feb 13, 2024·0 cites·3 claims
- 0762US2024142467A1Use of Biomarkers in the Treatment of Fibrotic Conditions with a PDE4B-inhibitorBOEHRINGER INGELHEIM INT·Filed 2023·Application pending·0 cites
- 0851US2019091216A1Macrolide compounds and their use in liver stage malaria and related diseaseUNIV JOHNS HOPKINS·Filed 2015·Application pending·0 cites
- 0946US2007179094A1Modulation of MDL-1 activity for treatment of inflammatory diseaseBAYER SCHERING PHARMA AG·Filed 2007·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Yi Liu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →